Atorvastatin

Dragon Pharma Atorvastatin 40mg — Cardiovascular Protection Statin

Dragon Pharma Atorvastatin delivers 40 mg of Atorvastatin Calcium per tablet. This HMG-CoA reductase inhibitor is engineered for athletes whose anabolic protocols compromise lipid homeostasis.

The compound suppresses de novo cholesterol biosynthesis in the liver. It lowers harmful low-density lipoprotein while supporting protective high-density lipoprotein, creating a safer cardiovascular environment during demanding cycles.

Overview

Atorvastatin Calcium is a synthetic lipid-lowering agent belonging to the statin class. It functions through competitive inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in hepatic cholesterol production.

Anabolic compounds, particularly oral C17-alkylated steroids and strong androgens, frequently depress HDL and elevate LDL. These shifts accelerate atherogenic risk and vascular inflammation when left unmanaged.

By blocking the mevalonate pathway, Atorvastatin reduces circulating LDL particles and upregulates hepatic LDL receptor expression. This enhances clearance of cholesterol from the bloodstream and supports arterial endothelial function.

Dragon Pharma manufactures each tablet under stringent quality protocols. Independent laboratory analysis confirms accurate 40 mg dosing for reliable therapeutic outcomes.

Benefits

• Dramatic LDL Reduction: Inhibits hepatic cholesterol synthesis, lowering harmful low-density lipoprotein particles that contribute to arterial plaque formation.
• HDL Support: Helps preserve or modestly elevate protective high-density lipoprotein, improving the atherogenic lipid ratio.
• Triglyceride Management: Reduces circulating triglyceride levels, addressing another key marker of metabolic and cardiovascular stress.
• Arterial Protection: Supports endothelial integrity and reduces systemic inflammation, protecting vascular health during extended anabolic exposure.
• Cycle Safety Net: Allows athletes to run demanding protocols with greater confidence in their long-term cardiovascular outcomes.

Main Features

• Precisely dosed 40 mg tablets for potent lipid management
• HMG-CoA reductase competitive inhibitor
• Blocks hepatic de novo cholesterol biosynthesis
• Upregulates LDL receptor expression for enhanced clearance
• Compatible with on-cycle support and PCT protocols
• Independent laboratory verification of tablet potency

Ingredients

Each tablet contains 40 mg of Atorvastatin Calcium as the active pharmaceutical ingredient.

Inactive excipients include microcrystalline cellulose, lactose monohydrate, magnesium stearate, and pharmaceutical-grade film-coating agents to ensure tablet stability and consistent dissolution.

All raw materials undergo identity and purity validation prior to compression and packaging.

How to Use

Ingest one tablet daily with water, with or without food. Evening administration is often preferred as hepatic cholesterol synthesis peaks during nighttime hours.

Consistency in daily timing supports stable plasma concentrations and optimal enzymatic inhibition.

Store the container in a cool, dry environment between 15–25°C (59–77°F). Protect from moisture and direct light. Keep the desiccant pouch intact.

Dosage

The standard therapeutic starting point is 10–20 mg daily. For athletes experiencing significant lipid disruption from anabolic compounds, 40 mg daily provides more aggressive management.

Always base dosing on pre-cycle, mid-cycle, and post-cycle blood work. Adjust under appropriate guidance according to individual lipid panel results.

Continue administration throughout the entire cycle and into Post-Cycle Therapy until fasting lipids normalize within healthy reference ranges.

Side Effects

Muscular symptoms including soreness, weakness, or myalgia are the most commonly discussed adverse effects. These are typically mild and dose-dependent.

If unusual or severe muscle pain develops, particularly when combined with other compounds, discontinue immediately and seek medical evaluation.

Hepatic enzyme elevations may occur. Regular liver function panels are essential, especially when stacking with hepatotoxic oral steroids.

Other reported effects include headache, mild gastrointestinal discomfort, and transient joint pain. These generally resolve without intervention.

Safety Information

This product is intended exclusively for research purposes and use by qualified adults under appropriate supervision. It is not suitable for minors, pregnant or nursing women, or individuals with pre-existing hepatic, renal, or muscular disorders.

Regular blood work monitoring fasting lipids, liver enzymes, and creatine kinase is mandatory. This ensures both therapeutic efficacy and early detection of adverse effects.

Avoid grapefruit and grapefruit juice during administration. These inhibit CYP3A4 metabolism and can dangerously amplify statin plasma concentrations.

Maintain a heart-healthy diet low in saturated fats and refined carbohydrates. Regular cardiovascular exercise complements pharmacological lipid management.

Discontinue immediately and seek medical evaluation if severe muscle pain, dark urine, jaundice, or profound weakness develop.